EARLY ALZHEIMER´S DISEASE
Clinical trials for EARLY ALZHEIMER´S DISEASE explained in plain language.
Never miss a new study
Get alerted when new EARLY ALZHEIMER´S DISEASE trials appear
Sign up with your email to follow new studies for EARLY ALZHEIMER´S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could this pill slow Alzheimer's? new trial hopes to find out
Disease control OngoingThis study tests an experimental drug called CT1812 in 540 people with early Alzheimer's disease. Participants take either a low dose, high dose, or a placebo pill for 18 months. The goal is to see if the drug can slow down memory and thinking problems. This is a Phase 2 trial, m…
Matched conditions: EARLY ALZHEIMER´S DISEASE
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
Experimental Alzheimer's drug targets tau in Early-Stage patients
Disease control OngoingThis study tests a single injection of a drug called NIO752 in 38 adults aged 30-74 with early Alzheimer's or mild cognitive impairment due to Alzheimer's. The main goal is to see if the drug can lower levels of tau protein in the spinal fluid, which is linked to Alzheimer's dama…
Matched conditions: EARLY ALZHEIMER´S DISEASE
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New hope for Alzheimer's: Long-Term drug trial targets High-Risk gene carriers
Disease control OngoingThis study looks at the long-term safety and effects of a drug called ALZ-801 in people with early Alzheimer's disease who have a specific gene (APOE4/4). About 163 participants who completed an earlier phase 3 trial will take the drug for up to 2 more years. Researchers will tra…
Matched conditions: EARLY ALZHEIMER´S DISEASE
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Promising Alzheimer's drug lecanemab tested in 1,900 patients
Disease control OngoingThis study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is t…
Matched conditions: EARLY ALZHEIMER´S DISEASE
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC